参考文献
[1]Jackson GL,Zullig LL,Zafar SY,et al.Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration[J].J Natl Compr Canc Netw.2013; 11(4):431-41.
[2]Japanese Gastric Cancer A.Japanese classification of gastric carcinoma:3rd English edition[J].Gastric Cancer.2011; 14(2):101-12.
[3]Van Cutsem E,Van de Velde C,Roth A,et al.Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group[J].Eur J Cancer.2008; 44(2):182-94.
[4]Moehler M,Al-Batran SE,Andus T,et al.German S3-guideline“Diagnosis and treatment of esophagogastric cancer”[J].Z Gastroenterol.2011; 49(4):461-531.
[5]Waddell T,Verheij M,Allum W,et al.Gastric cancer:ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol.2013; 24 Suppl 6:vi57-63.
[6]Ychou M,Boige V,Pignon JP,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase Ⅲ trial[J].J Clin Oncol.2011; 29(13):1715-21.
[7]Japanese Gastric Cancer A.Japanese gastric cancer treatment guidelines 2010 (ver.3)[J].Gastric Cancer.2011; 14(2):113-23.
[8]Lee JH,Kim JG,Jung HK,et al.Synopsis on clinical practice guideline of gastric cancer in Korea:an evidence-based approach[J].Korean J Gastroenterol.2014; 63(2):66-81.
[9]August DA,Gannon C.Guest editorial:Neoadjuvant therapy,predictors of response,and patient outcomes[J].J Surg Oncol.2010; 102(2):107-8.
[10]Li ZY,Koh CE,Bu ZD,et al.Neoadjuvant chemotherapy with FOLFOX:improved outcomes in Chinese patients with locally advanced gastric cancer[J].J Surg Oncol.2012; 105(8):793-9.
[11]Fink U,Schuhmacher C,Stein HJ,et al.Preoperative chemotherapy for stage Ⅲ-Ⅳ gastric carcinoma:feasibility,response and outcome after complete resection[J].Br J Surg.1995; 82(9):1248-52.
[12]Kobayashi T,Kimura T.Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer[J].Gan To Kagaku Ryoho.2000; 27(10):1521-6.
[13]Hartgrink HH,van de Velde CJ,Putter H,et al.Neo-adjuvant chemotherapy for operable gastric cancer:long term results of the Dutch randomised FAMTX trial[J].Eur J Surg Oncol.2004; 30(6):643-9.
[14]Zhang CW,Zou SC,Shi D,et al.Clinical significance of preoperative regional intra-arterial infusion chemotherapy for advanced gastric cancer[J].World J Gastroenterol.2004; 10(20):3070-2.
[15]Yoshikawa T,Tsuburaya A,Kobayashi O,et al.Neoadjuvant chemotherapy with a combination of irinotecan and cisplatin in advanced gastric cancer-a case report[J].Hepatogastroenterology.2000; 47(36):1575-8.
[16]Cai HB,Chen HZ,Yin HH.Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer[J].J Obstet Gynaecol Res.2006; 32(3):315-23.
[17]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[18]关晓辉.胃癌的诊治进展[J].北华大学学报（自然科学版），2019,20(05):670-674.
[19]Li T,Guo H,Zhao X,et al.Gastric Cancer Cell Proliferation and Survival Is Enabled by a Cyclophilin B/STAT3/miR-520d-5p Signaling Feedback Loop[J].Cancer Res,2017,77(5):1227-1240.
[20]Fuchs C S,Tomasek J,Yong C J,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial[J].Lancet,2014,383(9911):31-39.
[21]Wilke H,Muro K,Van Cutsem E,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind,randomised phase 3 trial[J].Lancet Oncol,2014,15(11):1224-1235.(https://www.daowen.com)
[22]Fuchs C S,Doi T,Jang R W,et al.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer:Phase 2 Clinical KEYNOTE-059 Trial[J].JAMA Oncol,2018,4(5):e180013.
[23]Keller S,Zwingenberger G,Ebert K,et al.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines[J].Mol Oncol,2018,12(4):441-462.
[24]Dhritlahre R K,Saneja A.Recent advances in HER2-targeted delivery for cancer therapy[J].Drug Discov Today,2021,26(5):1319-1329.
[25]Bai Z G,Zhang Z T.A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer[J].Onco Targets Ther,2018,11:7077-7087.
[26]Van Cutsem E,Bang Y J,Mansoor W,et al.A randomized,open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification[J].Ann Oncol,2017,28(6):1316-1324.
[27]Bang Y J,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[28]Rivera F,Romero C,Jimenez-Fonseca P,et al.Phase Ⅱ study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer:HERXO trial[J].Cancer Chemother Pharmacol,2019,83(6):1175-1181.
[29]Catenacci D,Tebbutt N C,Davidenko I,et al.Rilotumumab plus epirubicin,cisplatin,and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2017,18 (11):1467-1482.
[30]Moehler M,Shitara K,Garrido M,et al.LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC):First results of the CheckMate 649 study[J].Annals of Oncology,2020,31(Supl.4):S1191-S1191.,2020.
[31]Fuchs C S,Doi T,Jang R W,et al.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer:Phase 2 Clinical KEYNOTE-059 Trial[J].JAMA Oncol,2018,4(5):e180013.
[32]Shitara K,Ozguroglu M,Bang Y J,et al.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061):a randomised,open-label,controlled,phase 3 trial[J].Lancet,2018,392(10142):123-133.
[33]Kang Y K,Boku N,Satoh T,et al.Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens (ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebocontrolled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.
[34]Janjigian Y Y,Bendell J,Calvo E,et al.CheckMate-032 Study:Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer[J].J Clin Oncol,2018,36(28):2836-2844.
[35]Boku N,Ryu M H,Kato K,et al.Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer:interim results of a randomized,phase Ⅱ trial (ATTRACTION-4)[J].Ann Oncol,2019,30(2):250-258.
[36]Bang Y J,Ruiz E Y,Van Cutsem E,et al.Phase Ⅲ,randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer:primary analysis of JAVELIN Gastric 300[J].Ann Oncol,2018,29(10):2052-2060.
[37]Derks S,de Klerk L K,Xu X,et al.Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas[J].Ann Oncol,2020,31(8):1011-1020.
[38]Peng Z,Cheng S,Kou Y,et al.The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer[J].Cancer Immunol Res,2020,8(10):1251-1261.
[39]Li Z,Gao X,Peng X,et al.Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy[J].Sci Adv,2020,6(9):y4211.
[40]Kumagai S,Togashi Y,Sakai C,et al.An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells[J].Immunity,2020,53(1):187-203.
[41]Wang R,Song S,Harada K,et al.Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response[J].Gut,2020,69(1):18-31.
[42]Zhang H,Schaefer A,Wang Y,et al.Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer[J].Cancer Discov,2020,10(2):288-305.